Fat accumulation in muscles caused by Cushing’s syndrome leads to impaired muscle function and worse physical performance long after patients have achieved remission with normal cortisol levels, findings from a new study show. The study, “Thigh muscle fat infiltration is associated with impaired physical performance despite…
Ectopic ACTH-secreting pituitary adenomas (EAPAs), a rare cause of Cushing’s disease, are more commonly found in women, who also have a poorer prognosis than men with the same condition, a study suggests. Titled “Long-term follow-up for ectopic ACTH-secreting pituitary adenoma in a single tertiary medical…
Recordati‘s inhibitor of cortisol synthesis, Isturisa (osilodrostat), has been approved by the European Commission (EC) for the treatment of people with endogenous Cushing’s syndrome, the company announced. The decision follows a European Medicines Agency (EMA) committee recommendation in November to approve Isturisa for that…
One year of treatment with under-the-skin Signifor (pasireotide) lessens tumor volume in many Cushing’s disease patients for whom surgery has failed or is not an option, a post-hoc analysis of a Phase 3 clinical trial shows. Signifor was found to normalize urinary cortisol levels and ease…
People diagnosed with Cushing’s disease during childhood may experience lowered pituitary hormones long after receiving surgery, as well as mood and cognitive disorders, a long-term follow-up study shows. The study, “Long-Term Outcome in Patients After Treatment for Cushing’s Disease in Childhood,” was published in the journal PLoS…
A diagnostic technique called bilateral inferior petrosal sinus sampling (BIPSS), which measures the levels of the adrenocorticotropic hormone (ACTH) produced by the pituitary gland, should only be used to diagnose cyclic Cushing’s syndrome patients during periods of cortisol excess, a case report shows. When it…
People with Cushing’s syndrome often experience a rise in blood pressure that puts them at a significant risk of cardiovascular ills, but most improve within 10 days after surgery to treat their hypercortisolism, a study found. Nonetheless, fewer than half see their blood pressure normalized within one year of surgical…
Cushing’s disease patients who are treated with cabergoline while undergoing conventional fractionated radiotherapy have a higher risk of disease recurrence after initial remission, a small study has found. The study, “Cabergoline may act as a radioprotective agent in Cushing’s disease,” was published in Clinical Endocrinology. Radiation…
On average, people with Cushing’s syndrome wait 34 months before receiving a definite diagnosis, but waiting time largely depends on their specific disease subtype, a review study from Germany reports. Cushing’s disease patients — those with a tumor in the pituitary gland — wait the longest for a…
A Phase 3 trial evaluating Corcept Therapeutics‘ relacorilant in treating the high blood pressure and poorer glucose tolerance in people with endogenous Cushing’s syndrome has begun dosing patients in Europe, the company announced. The GRACE trial (NCT03697109) will be conducted at 62 sites in the United States,…
Get regular updates to your inbox.